[1]Southeast University, Department of Pathogenic Biology and Immunology,Nanjing,China
[2]Fudan University, Department of Immunology,Shanghai,China
[3]Chinese Academy of Sciences, National Astronomical Observatories,Beijing,China
[4]Vanderbilt University School of Medicine, Department of Cell and Developmental Biology,Nashville,United States
[5]National Institute on Aging, Laboratory of Molecular Biology and Immunology,Bethesda,United States
To assess GM-CSF immune accessory effects in tumor-bearing mice, an animal tumor model was established by inoculating SP2/0 myeloma cells s.c. into the flank of Balb/c mice and 14 days later, injecting either 400 μg recombinant pcDNA3.1/mGM-CSF or a blank plasmid s.c. or i.m. into the tumor four times. The tumor weight, the activities of CTL and NK, the serum levels of IFN-γ, IL-2 and lymphocytes infiltrating in tumor tissue were analysed 8 weeks later with MTT, ELISA and pathological section methods. The results showed that the tumor lump was reduced in mice injected s.c. (0.880 ± 0.405 g) or i.m. (0.378 ± 0.411 g) with pcDNA3.1/mGM-CSF compared with control mice injected s.c. (1.548 ± 0.221g, P < 0.01)or i.m. (1.554 ± 0.249g, P < 0.001) with a blank vector. Lymphocyte infiltration in tumor tissues was very apparent in mice injected i.m. with pcDNA3.1/mGM-CSF. In contrast, there was no lymphocyte infiltration in tumor tissues of control mice. In addition, the serum concentrations of IFN-γ, IL-2 and the activities of CTL and NK cells were significantly increased in mice injected with pcDNA3.1/mGM-CSF compared with a control mice (P < 0.01). In conclusion, direct gene immunization of recombinant pcDNA3.1/mGM-CSF is a feasible strategy for tumor therapy. Copyright ? Taylor & Francis Group, LLC.
(8.0+极速模式)